XENLETA (Lefamulin Acetate) Patent Expiration, LOE Window & CMS Spending

XENLETA (Lefamulin Acetate) by Hong Kong King Friend Industrial: FDA Orange Book core substance LOE 2033-03-25, 0 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorHong Kong King Friend Industrial
FDA Application & PathwayN211672 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2033-03-25
Last Listed Patent or Exclusivity Date2033-03-25
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel